Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data

Figures & data

Table 1 Ongoing or Completed Vaccine Trials with the HER2_369-377 Peptide and Associated Adjuvants Used and Systemic Therapies Combined with the Peptide

Trial Number	Patients	Vaccine Antigen(s)	Adjuvant	Systemic Therapy	Ref	Number of participants	First Author
NCT02636582	DCIS	E75	GM-CSF	None	[^Citation23]	13	Mittendorf
NCT02297698	HER2+ breast cancer	E75 vs GM-CSF	GM-CSF	Trastuzumab	[^Citation22]	100	Peace
NCT01479244	Breast cancer with low-intermediate HER2	E75 vs placebo	GM-CSF	None	[^Citation3]	758	Mittendorf
NCT00841399	Breast cancer	E75	GM-CSF	None	[^Citation18^–^Citation20]	100	Mittendorf
NCT00854789	Breast cancer	E75	GM-CSF	None	[^Citation17^–^Citation19]	95	Mittendorf
NCT01570036	Breast cancer	E75	GM-CSF	Trastuzumab	[^Citation1]	275	Clifton
NCT00266110	Breast cancer	E75	Dendritic cells	Trastuzumab + vinorelbine	[^Citation26]	17	Serody
Zaks ‘98	Breast, ovarian, and colorectal cancer	E75	Incomplete Freund’s	None	[^Citation15]	4	Zaks
Knutson ‘02	Breast/ovarian Cancer	E75	GM-CSF	None	[^Citation16]	6	Knutson
Murray ‘02	Breast/ovarian Cancer	E75	GM-CSF	None	[^Citation17]	14	Murray

Mittendorf ElizabethA, PlitasG, GarberJ, et al. Abstract OT3-01-04: VADIS trial: phase II trial of the nelipepimut-S peptide vaccine in women with DCIS of the breast. Paper presented at: San Antonio Breast Cancer Symposium; 2016; San Antonio, TX.

 Google Scholar

PeaceKM, LittonJK, MurthyRK, et al. Pre-specified interim analysis in a prospective, randomized phase II trial of trastuzumab vs trastuzumab + NeuVax to prevent breast cancer recurrence in HER2+ breast cancer patients. Paper presented at: American Association of Cancer Researchers, Annual Meeting; 2017; Washington, DC.

 Google Scholar

MittendorfEA, LuB, MeliskoM, et al. Efficacy and safety analysis of Nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial. Clin Cancer Res. 2019;25(14):4248–4254. doi:10.1158/1078-0432.CCR-18-286731036542

 PubMed Web of Science ®Google Scholar

MittendorfEA, CliftonGT, HolmesJP, et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25(9):1735–1742. doi:10.1093/annonc/mdu21124907636

 PubMed Web of Science ®Google Scholar

PeoplesGE, HolmesJP, HuemanMT, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2008;14(3):797–803. doi:10.1158/1078-0432.CCR-07-144818245541

 PubMed Web of Science ®Google Scholar

MurrayJL, GilloglyME, PrzepiorkaD, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2002;8(11):3407–3418.12429628

 PubMed Web of Science ®Google Scholar

PeoplesGE, GurneyJM, HuemanMT, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J clin oncol. 2005;23(30):7536–7545. doi:10.1200/JCO.2005.03.04716157940

 PubMed Web of Science ®Google Scholar

CliftonGT, HaleD, VreelandTJ. et al. Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab vs trastuzumab to prevent recurrences in high-risk HER2 low-expressing breast cancer patients. Clin Cancer Res. 2020:clincanres.2741.2019. doi:10.1158/1078-0432.CCR-19-2741

 Web of Science ®Google Scholar

SerodyJ; 2020 Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT00266110. Accessed 311, 2020.

 Google Scholar

ZaksTZ, RosenbergSA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 1998;58(21):4902–4908.9809997

 PubMed Web of Science ®Google Scholar

KnutsonKL, SchiffmanK, CheeverMA, DisisML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res. 2002;8(5):1014–1018.

 PubMed Web of Science ®Google Scholar